Anthony Victor D'Amico, MD, PhD, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, discusses a personalized approach to active surveillance in localized prostate cancer, including the stratification of men by comorbidity. Patients with poor health are ideal candidates for active surveillance. However, for select patients with favorable intermediate-risk prostate cancer treatment may be reasonable, including patients with minimal comorbidity and factors that predict for more aggressive cancer, such as PSA density, whether the disease is visible on MRI, BMI and age. Prof. D'Amico additionally talks on machine-based learning and its ability to predict adverse pathology at prostatectomy in men with otherwise favorable indices. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
